Englewood Lab (A950140) Q4 2024 earnings summary

Executive summary

• 2024 saw a challenging global economic environment with consumer slowdown, geopolitical tensions, and currency volatility, impacting business conditions.

• Consolidated revenue for 2024 was $133.6M, with operating income of $13.8M and net income of $14.4M, reflecting a year-over-year decline in sales and profitability.

• The company maintained a strong financial structure, with a consolidated debt ratio of 38.8% and equity ratio of 72.0%.

• The business focuses on ODM/OEM cosmetics manufacturing, leveraging proprietary formulations and OTC expertise to strengthen market position.

Financial highlights

• Consolidated revenue decreased 15.7% year-over-year to $133.6M; operating income fell 37.7% to $13.8M; net income declined 9.4% to $14.4M.

• Cash and equivalents more than doubled to $19.1M, while accounts receivable dropped 19.5% to $42.1M.

• Inventory decreased 16.2% to $27.3M; total assets rose slightly by 0.9% to $135.9M.

• Debt reduced by 16.6% to $38.0M; equity increased 9.8% to $97.9M.

• Earnings per share (basic/diluted) were $0.72, down from $0.80 in 2023.

Outlook and guidance

• The company anticipates continued economic uncertainty in 2025 due to protectionist trade policies and currency risks.

• Plans include automation investments and strengthening its position as a leading U.S. cosmetics ODM provider.